PARSIPPANY, N.J. and TEL AVIV, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a study of treatment patterns among patients with tardive dyskinesia (TD) residing in long-term care (LTC) facilities, highlighting a critical gap in TD diagnosis and…
Press Release: New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025 - Newscast
Tue, 03 Jun 2025 11:14:00 GMT New data show that Uzedy significantly reduces relapse and healthcare utilization, while TEV-'749 has demonstrated strong efficacy with no post-injection delirium/sedation syndrome to date—advancing ...
Sat, 31 May 2025 09:34:00 GMT Full results from the study were presented at Psych Congress Elevate on May 30, 2025, with additional data ... www.tevapharm.com. Teva Cautionary Note Regarding Forward Looking Statements This ...
Fri, 30 May 2025 17:01:00 GMT To learn more about how Teva is all in for better health, visit www.tevapharm.com. This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform ...
Thu, 29 May 2025 17:00:00 GMT TEVA), today announced the presentation of real-world clinical outcomes, treatment patterns and healthcare resource utilization (HCRU) data evaluating UZEDY® (risperidone), an extended-release ...
Thu, 29 May 2025 17:00:00 GMT which can lead to incorrect treatment options for TD Teva is committed to continuing to advance research to better understand and help address unmet needs among patients living with TD in LTC ...
